JPWO2020188348A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020188348A5 JPWO2020188348A5 JP2021556481A JP2021556481A JPWO2020188348A5 JP WO2020188348 A5 JPWO2020188348 A5 JP WO2020188348A5 JP 2021556481 A JP2021556481 A JP 2021556481A JP 2021556481 A JP2021556481 A JP 2021556481A JP WO2020188348 A5 JPWO2020188348 A5 JP WO2020188348A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- polynucleotide
- modified
- chain
- host cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819988P | 2019-03-18 | 2019-03-18 | |
| US62/819,988 | 2019-03-18 | ||
| PCT/IB2020/000140 WO2020188348A2 (en) | 2019-03-18 | 2020-03-17 | A2/ny-eso-1 specific t cell receptors and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022525925A JP2022525925A (ja) | 2022-05-20 |
| JPWO2020188348A5 true JPWO2020188348A5 (https=) | 2023-03-17 |
| JP2022525925A5 JP2022525925A5 (https=) | 2023-03-17 |
| JP7680032B2 JP7680032B2 (ja) | 2025-05-20 |
Family
ID=70465122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556481A Active JP7680032B2 (ja) | 2019-03-18 | 2020-03-17 | Ａ２／ｎｙ－ｅｓｏ－１特異的ｔ細胞受容体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12473346B2 (https=) |
| EP (1) | EP3941939A2 (https=) |
| JP (1) | JP7680032B2 (https=) |
| CN (1) | CN113906140B (https=) |
| AU (1) | AU2020243431B2 (https=) |
| CA (1) | CA3134102A1 (https=) |
| WO (1) | WO2020188348A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| EP4217738A1 (en) * | 2020-09-27 | 2023-08-02 | Genentech, Inc. | High throughput multiparametric immune cell engager screening assay |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| US20240207319A1 (en) | 2021-05-06 | 2024-06-27 | Ludwig Institute For Cancer Research Ltd | Compositions and methods for immunotherapy |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| EP4374872A1 (en) * | 2022-11-22 | 2024-05-29 | Koninklijke Philips N.V. | Pde enhanced car-t cells |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5617900A (en) | 1999-06-17 | 2001-01-09 | Robert C. Gallo | Chimeric chemokine-antigen polypeptides and uses therefor |
| AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
| NZ550815A (en) | 2004-05-19 | 2009-04-30 | Immunocore Ltd | Method of improving T cell receptors |
| DK1765860T3 (da) | 2004-05-19 | 2009-03-09 | Immunocore Ltd | Ny-ESO-T.cellereceptor med höj affinitet |
| EP3479844B1 (en) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| WO2008039818A2 (en) * | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| WO2008037943A1 (en) | 2006-09-29 | 2008-04-03 | Medigene Limited | Cells transformed with nucleic acid encoding ny-eso t cell receptors |
| US20100297093A1 (en) * | 2007-09-25 | 2010-11-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Modified t cell receptors and related materials and methods |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| SI2804617T1 (sl) | 2012-01-17 | 2020-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Visokoafinitetni SIRP-alfa reagenti |
| PT2961831T (pt) | 2013-02-26 | 2020-10-12 | Memorial Sloan Kettering Cancer Center | Composições e métodos para imunoterapêutica |
| WO2016069282A1 (en) * | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| EP3377523A4 (en) * | 2015-11-19 | 2019-06-19 | The Regents of The University of California | CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| CN108456247A (zh) | 2017-02-20 | 2018-08-28 | 上海恒润达生生物科技有限公司 | 靶向ny-eso-1的t细胞受体及其用途 |
-
2020
- 2020-03-17 AU AU2020243431A patent/AU2020243431B2/en active Active
- 2020-03-17 EP EP20721721.7A patent/EP3941939A2/en active Pending
- 2020-03-17 CA CA3134102A patent/CA3134102A1/en active Pending
- 2020-03-17 CN CN202080031738.8A patent/CN113906140B/zh active Active
- 2020-03-17 JP JP2021556481A patent/JP7680032B2/ja active Active
- 2020-03-17 US US17/440,136 patent/US12473346B2/en active Active
- 2020-03-17 WO PCT/IB2020/000140 patent/WO2020188348A2/en not_active Ceased
-
2025
- 2025-10-17 US US19/361,931 patent/US20260103503A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dudley et al. | Adoptive cell transfer therapy | |
| Redeker et al. | Improving adoptive T cell therapy: the particular role of T cell costimulation, cytokines, and post-transfer vaccination | |
| Spear et al. | Strategies to genetically engineer T cells for cancer immunotherapy | |
| Maher | Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells | |
| CN109575143B (zh) | 双特异性cd20-cd19-car及其应用 | |
| JP2021168667A (ja) | 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用 | |
| EA027153B1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| CN108472365A (zh) | 用于肿瘤转导的组合物和方法 | |
| Yang et al. | Adoptive cellular therapy (ACT) for cancer treatment | |
| JP2021501567A (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞−抗原カプラおよびその方法ならびに使用 | |
| WO2018145648A1 (zh) | 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定 | |
| JP7564369B2 (ja) | がん及び自己免疫疾患及び炎症性疾患を治療する方法 | |
| WO2023083192A1 (zh) | 联合表达CCR2b和CD40L的工程化免疫细胞及其制备和应用 | |
| WO2018199595A1 (ko) | 4-1bbl 변이체 및 이를 포함하는 융합 단백질 | |
| US12415843B2 (en) | Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer | |
| WO2018121679A1 (zh) | 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途 | |
| Hege et al. | T-cell gene therapy | |
| CN116836299B (zh) | 嵌合抗原受体及其应用 | |
| CN114555815B (zh) | T细胞受体及其使用方法 | |
| JPWO2020188348A5 (https=) | ||
| JPWO2019236577A5 (https=) | ||
| Haas et al. | Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine. | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| KR20220038776A (ko) | T 세포 수용체 및 이의 사용 방법 |